N-Acetyl-Alpha-D-Galactosaminidase Deficiency Type 3 Latest Advances

Unique bifunctional α-sialidase/β-N-acetylgalactosaminidase from Bifidobacterium bifidum acting on the Sda antigen.

Journal: The Journal of biological chemistry

Published: October 23, 2025

Enzyme replacement therapy using a modified α-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic/Gla-knockout mice.

Journal: Molecular genetics and metabolism

Published: March 10, 2025

Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.

Journal: International journal of physiology, pathophysiology and pharmacology

Published: November 04, 2024

Carving out a Glycoside Hydrolase Active Site for Incorporation into a New Protein Scaffold Using Deep Network Hallucination.

Journal: ACS synthetic biology

Published: February 15, 2024

Potent and Selective Cell-Active Iminosugar Inhibitors of Human α-N-Acetylgalactosaminidase (α-NAGAL).

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: March 28, 2023

Effect of Phlorotannins from Brown Algae Costaria costata on α-N-Acetylgalactosaminidase Produced by Duodenal Adenocarcinoma and Melanoma Cells.

Journal: Marine drugs

Published: December 10, 2022

Low α-N-acetylgalactosaminidase plasma concentration correlates with the presence and severity of the bipolar affective disorder.

Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

Published: September 14, 2022

Identification of dual active sites in Caenorhabditis elegans GANA-1 protein: an ortholog of the human α-GAL a and α-NAGA enzymes.

Journal: Journal of biomolecular structure & dynamics

Published: June 13, 2022

Could low α-N-acetylgalactosaminidase plasma concentration cause schizophrenia?

Journal: The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry

Published: May 06, 2022

Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11.

Journal: Molecular genetics and metabolism reports

Published: April 13, 2022

Engineering Bifidobacterium longum Endo-α-N-acetylgalactosaminidase for Neu5Acα2-3Galβ1-3GalNAc reactivity on Fetuin.

Journal: Archives of biochemistry and biophysics

Published: February 16, 2022

Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.

Journal: Cancer treatment and research communications

Published: January 13, 2022

N-Acetyl-Alpha-D-Galactosaminidase Deficiency Type 3 Latest Advances

Find the Latest Research About N-Acetyl-Alpha-D-Galactosaminidase Deficiency Type 3

Unique bifunctional α-sialidase/β-N-acetylgalactosaminidase from Bifidobacterium bifidum acting on the Sda antigen.

Unique bifunctional α-sialidase/β-N-acetylgalactosaminidase from Bifidobacterium bifidum acting on the Sda antigen.

Enzyme replacement therapy using a modified α-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic/Gla-knockout mice.

Enzyme replacement therapy using a modified α-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic/Gla-knockout mice.

Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.

Alpha-N-acetylgalactosaminidase in cancer: diagnostic applications and related treatment strategies.

Carving out a Glycoside Hydrolase Active Site for Incorporation into a New Protein Scaffold Using Deep Network Hallucination.

Carving out a Glycoside Hydrolase Active Site for Incorporation into a New Protein Scaffold Using Deep Network Hallucination.

Potent and Selective Cell-Active Iminosugar Inhibitors of Human α-N-Acetylgalactosaminidase (α-NAGAL).

Potent and Selective Cell-Active Iminosugar Inhibitors of Human α-N-Acetylgalactosaminidase (α-NAGAL).

Effect of Phlorotannins from Brown Algae Costaria costata on α-N-Acetylgalactosaminidase Produced by Duodenal Adenocarcinoma and Melanoma Cells.

Effect of Phlorotannins from Brown Algae Costaria costata on α-N-Acetylgalactosaminidase Produced by Duodenal Adenocarcinoma and Melanoma Cells.

Low α-N-acetylgalactosaminidase plasma concentration correlates with the presence and severity of the bipolar affective disorder.

Low α-N-acetylgalactosaminidase plasma concentration correlates with the presence and severity of the bipolar affective disorder.

Identification of dual active sites in Caenorhabditis elegans GANA-1 protein: an ortholog of the human α-GAL a and α-NAGA enzymes.

Identification of dual active sites in Caenorhabditis elegans GANA-1 protein: an ortholog of the human α-GAL a and α-NAGA enzymes.

Could low α-N-acetylgalactosaminidase plasma concentration cause schizophrenia?

Could low α-N-acetylgalactosaminidase plasma concentration cause schizophrenia?

Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11.

Generation of an in vitro model for peripheral neuropathy in Fabry disease using CRISPR-Cas9 in the nociceptive dorsal root ganglion cell line 50B11.

Engineering Bifidobacterium longum Endo-α-N-acetylgalactosaminidase for Neu5Acα2-3Galβ1-3GalNAc reactivity on Fetuin.

Engineering Bifidobacterium longum Endo-α-N-acetylgalactosaminidase for Neu5Acα2-3Galβ1-3GalNAc reactivity on Fetuin.

Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.

Immunotherapy with GcMAF revisited - A critical overview of the research of Nobuto Yamamoto.